- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
China on the Cusp of Anticancer Biosimilar Wave, Report Says
China’s biosimilar development engine is supercharged and running on octane, a recent report said.
China has lagged in the adoption of anticancer biosimilars, but a huge number of agents in development suggest an “incoming wave” of these agents is about to hit, according to authors of a recent study.
Just 2 anticancer biosimilars were approved in China by the end of 2019, but the country has 23.9% of the global cancer burden. The turning point in China could occur very soon, the authors said, noting that 54 anticancer biosimilars representing 7 reference products are under clinical development in mainland China, 3 are involved in new drug application reviews, and 27 are in late-phase efficacy comparative studies.
These findings were included in a report of biosimilar adoption in 40 countries with 78.1% of the worldwide cancer incidence. China’s biosimilar development engine is supercharged and running on octane, the report said.
Visit The Center for Biosimilars for the full story.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD
October 30th 2024Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).
Read More
